Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

NCT05220410 is registered in ClinicalTrials.gov with Sheppard Pratt Health System as lead sponsor.

NCT NCT05220410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05220410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
Lead sponsor
Sheppard Pratt Health System
Phase
Phase 2
Overall status
Completed
Start date
March 28, 2022
Completion date
May 12, 2025
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

suicidal ideation, treatment resistant depression